New pill aims to slow MS progression in 990-patient global trial
NCT ID NCT07299019
First seen Jan 06, 2026 · Last updated May 05, 2026 · Updated 19 times
Summary
This study tests an oral drug called orelabrutinib against a placebo in about 990 adults aged 18-60 with non-active secondary progressive multiple sclerosis (SPMS). The goal is to see if the drug can delay worsening disability over 12 to 60 months. Participants are randomly assigned to drug or placebo in a 2:1 ratio.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurology Associates
RECRUITINGMaitland, Florida, 32751, United States
Conditions
Explore the condition pages connected to this study.